Kingworld Medicines Group Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Li Sheng Zhao
İcra Kurulu Başkanı
CN¥1.5m
Toplam tazminat
| CEO maaş yüzdesi | 98.5% |
| CEO görev süresi | 16.2yrs |
| CEO sahipliği | 54.2% |
| Yönetim ortalama görev süresi | Veri yok |
| Yönetim Kurulu ortalama görev süresi | 14yrs |
Son yönetim güncellemeleri
Recent updates
The Returns On Capital At Kingworld Medicines Group (HKG:1110) Don't Inspire Confidence
Nov 13
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥31m |
| Mar 31 2024 | n/a | n/a | CN¥35m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥38m |
| Sep 30 2023 | n/a | n/a | CN¥37m |
| Jun 30 2023 | n/a | n/a | CN¥36m |
| Mar 31 2023 | n/a | n/a | CN¥29m |
| Dec 31 2022 | CN¥1m | CN¥1m | CN¥23m |
| Sep 30 2022 | n/a | n/a | CN¥29m |
| Jun 30 2022 | n/a | n/a | CN¥35m |
| Mar 31 2022 | n/a | n/a | CN¥33m |
| Dec 31 2021 | CN¥1m | CN¥1m | CN¥30m |
| Sep 30 2021 | n/a | n/a | CN¥26m |
| Jun 30 2021 | n/a | n/a | CN¥21m |
| Mar 31 2021 | n/a | n/a | CN¥17m |
| Dec 31 2020 | CN¥1m | CN¥1m | CN¥12m |
| Sep 30 2020 | n/a | n/a | CN¥16m |
| Jun 30 2020 | n/a | n/a | CN¥20m |
| Mar 31 2020 | n/a | n/a | CN¥32m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥43m |
| Sep 30 2019 | n/a | n/a | CN¥45m |
| Jun 30 2019 | n/a | n/a | CN¥46m |
| Mar 31 2019 | n/a | n/a | CN¥44m |
| Dec 31 2018 | CN¥1m | CN¥1m | CN¥41m |
| Sep 30 2018 | n/a | n/a | CN¥49m |
| Jun 30 2018 | n/a | n/a | CN¥56m |
| Mar 31 2018 | n/a | n/a | CN¥54m |
| Dec 31 2017 | CN¥2m | CN¥1m | CN¥51m |
Tazminat ve Piyasa: Li Sheng 'ın toplam tazminatı ($USD 200.51K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 233.02K ).
Tazminat ve Kazançlar: Li Sheng 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Li Sheng Zhao (66 yo)
16.2yrs
Görev süresi
CN¥1,452,000
Tazminat
Mr. Li Sheng Zhao is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | CN¥1.45m | 54.21% HK$ 138.3m | |
| Co-Founder & Executive Director | 16.2yrs | CN¥1.32m | 15.25% HK$ 38.9m | |
| Executive Director | 15.3yrs | CN¥483.00k | 0.45% HK$ 1.2m | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | 0.036% HK$ 91.1k | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | Veri yok | |
| Independent Non-Executive Director | 11.3yrs | CN¥285.00k | 0.042% HK$ 106.6k | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
14.0yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 1110 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14 yıldır).